Case-Based Learning: Unexplained Hemolysis With Normal Peripheral Smear

Abstract

Hemolysis is defined by premature red blood cell destruction and may be difficult to diagnose when the peripheral blood smear appears normal. A normal smear does not exclude clinically important intravascular or extravascular hemolysis, particularly in early disease, low-grade hemolysis, immune-mediated disorders, paroxysmal nocturnal hemoglobinuria, hereditary enzyme defects, or conditions in which abnormal cells are transient or sparsely distributed. This case-based review presents a structured approach to unexplained hemolysis, emphasizing integration of clinical findings, reticulocyte response, lactate dehydrogenase, indirect bilirubin, haptoglobin, direct antiglobulin testing, urinalysis, medication history, transfusion history, and targeted molecular or flow-cytometric investigations. The discussion highlights mechanism-based differential diagnosis, diagnostic pitfalls, treatment principles, emerging therapies, and guideline-informed clinical decision-making. Early recognition is important because apparently mild hemolysis may signal an underlying hematologic, autoimmune, infectious, cardiopulmonary, renal, or malignant process requiring disease-specific therapy.

Introduction

Hemolysis with a normal peripheral smear is a clinically important diagnostic problem because clinicians often associate hemolysis with conspicuous schistocytes, spherocytes, bite cells, sickle forms, or other morphologic abnormalities. In practice, red cell morphology may remain unremarkable when the rate of destruction is modest, when hemolysis occurs predominantly outside the circulation, or when the causative process affects red cell survival without producing a persistent morphologic signature. The diagnosis therefore depends on recognizing a biochemical pattern rather than relying on a single laboratory test. A typical profile includes an elevated reticulocyte count, increased lactate dehydrogenase, increased indirect bilirubin, reduced serum haptoglobin, and, in some patients, hemoglobinuria or hemosiderinuria.

The central clinical challenge is to distinguish true hemolysis from ineffective erythropoiesis, occult bleeding, liver disease, renal disease, hereditary anemia, and laboratory artifacts. A normal smear should prompt a broader evaluation rather than reassurance. The case-based approach is especially useful for physicians because it links pathophysiology to test selection and prevents premature closure after an initial negative evaluation.

Epidemiology / Disease Burden

Hemolytic anemia is not a single disease and its epidemiology varies according to age, geography, ethnicity, comorbid illness, medication exposure, and access to diagnostic testing. Autoimmune hemolytic anemia is uncommon but clinically consequential, with warm antibody disease representing the majority of cases and cold antibody-mediated disease occurring in association with clonal B-cell disorders, infection, or primary cold agglutinin disease. Glucose-6-phosphate dehydrogenase deficiency remains one of the most prevalent inherited enzymopathies worldwide, particularly in regions where malaria has exerted selective pressure. Hereditary spherocytosis, pyruvate kinase deficiency, unstable hemoglobin disorders, and membrane defects may present in adulthood when compensated hemolysis becomes clinically apparent during infection, pregnancy, surgery, or medication exposure.

Paroxysmal nocturnal hemoglobinuria is rare but potentially life-threatening because hemolysis may coexist with thrombosis, marrow failure, and renal injury. Mechanical hemolysis related to prosthetic valves, ventricular assist devices, severe hypertension, or microangiopathic processes contributes to morbidity even when fragmented cells are not initially seen. The overall burden includes fatigue, jaundice, pigment nephropathy, gallstone formation, thromboembolism, transfusion dependence, impaired work capacity, and complications of the underlying disease. Delayed diagnosis may increase avoidable transfusion, expose patients to inappropriate immunosuppression, and postpone treatment of malignancy or complement-mediated disease.

Pathophysiology

Hemolysis may be intravascular, extravascular, or mixed. Intravascular destruction releases free hemoglobin into plasma, saturates haptoglobin, promotes hemoglobinuria, and can cause nitric oxide depletion, vasoconstriction, endothelial dysfunction, and acute kidney injury. Extravascular hemolysis occurs mainly in the spleen and liver, where macrophages remove antibody-coated, rigid, or senescent red cells. This process commonly produces indirect hyperbilirubinemia and splenomegaly but may produce few distinctive smear abnormalities.

Immune hemolysis can result from immunoglobulin G warm antibodies, complement-fixing cold antibodies, drug-dependent antibodies, or alloantibodies after transfusion. Complement-mediated intravascular injury is central to paroxysmal nocturnal hemoglobinuria, in which an acquired PIGA mutation causes deficiency of glycosylphosphatidylinositol-linked proteins, including CD55 and CD59. Enzymopathies impair protection against oxidative stress or reduce adenosine triphosphate production. Membrane disorders increase splenic sequestration, while hemoglobinopathies can cause unstable or poorly deformable cells. The absence of visible abnormalities on smear may reflect low disease activity, sampling timing, technical limitations, rapid clearance of abnormal cells, or a mechanism that does not substantially alter cell morphology.

Risk Factors

Important risk factors include recent medications such as certain antibiotics, antimalarials, dapsone, sulfonamides, cephalosporins, methyldopa, and immune checkpoint inhibitors; recent transfusion; autoimmune disease; lymphoproliferative disorders; solid tumors; infections; pregnancy; prosthetic cardiac valves; extracorporeal mechanical support; severe burns; renal failure; and exposure to oxidant chemicals. A history of episodic jaundice, dark urine, neonatal anemia, splenectomy, gallstones at a young age, or anemia among relatives raises suspicion for inherited hemolysis. Travel or ancestry associated with G6PD deficiency, malaria, babesiosis, or hemoglobin disorders should be specifically documented.

Clinical risk assessment should also include alcohol use, nutritional status, transplant history, new supplements, recreational drugs, and occupational exposure. A complete transfusion history is essential because delayed hemolytic transfusion reactions can occur days after transfusion and may initially be missed if antibody screening is negative or the hemolytic episode is mild.

Clinical Features

Patients may report fatigue, exertional dyspnea, palpitations, reduced exercise tolerance, jaundice, scleral icterus, dark urine, abdominal discomfort, fever, or back pain. Intravascular hemolysis more often produces hemoglobinuria and acute pain, whereas extravascular hemolysis may present with splenomegaly, indirect jaundice, or pigment gallstones. Symptoms can be subtle when anemia develops gradually because cardiovascular and erythropoietic compensation occurs over time.

Physical examination should assess pallor, jaundice, splenic enlargement, lymphadenopathy, cardiac murmurs, prosthetic valve sounds, signs of thrombosis, renal dysfunction, infection, and connective tissue disease. Severe hemolysis may cause tachycardia, hypotension, heart failure, delirium, or acute kidney injury. The absence of jaundice or dark urine does not exclude hemolysis, particularly when hepatic conjugation is efficient or the process is predominantly extravascular.

Diagnosis

Initial testing should include a complete blood count with reticulocyte count, bilirubin fractions, lactate dehydrogenase, haptoglobin, creatinine, urinalysis, and direct antiglobulin testing. A corrected reticulocyte count or reticulocyte production index is more informative than the unadjusted reticulocyte percentage, particularly in severe anemia. Elevated lactate dehydrogenase, increased indirect bilirubin, and low haptoglobin strongly support hemolysis, although haptoglobin may be reduced in liver disease or congenital deficiency and may be increased during inflammation. Reticulocytopenia despite hemolysis suggests marrow suppression, nutrient deficiency, renal erythropoietin deficiency, parvovirus infection, or severe acute destruction that has outpaced marrow recovery.

The smear should be reviewed by an experienced morphologist, but a normal result must not terminate evaluation. Repeat examination during active symptoms may reveal transient abnormalities. Spherocytes can support warm autoimmune hemolysis or hereditary spherocytosis, while agglutination suggests cold antibody disease. Schistocytes raise concern for thrombotic microangiopathy, disseminated intravascular coagulation, malignant hypertension, or mechanical destruction, but their absence does not exclude these diagnoses. If the direct antiglobulin test is positive, monospecific testing for immunoglobulin G and complement, medication review, antibody identification, and evaluation for lymphoproliferative or autoimmune disease are appropriate.

Unexplained Coombs-negative hemolysis requires consideration of PNH, G6PD deficiency, pyruvate kinase deficiency, hereditary membrane disorders, unstable hemoglobin, occult infection, and mechanical causes. High-sensitivity flow cytometry using fluorescent aerolysin or evaluation of glycosylphosphatidylinositol-linked proteins is the preferred test for PNH. G6PD activity can be falsely normal during or shortly after an acute episode because young reticulocytes have higher enzyme activity; repeat testing after recovery may be necessary. Enzyme assays, osmotic gradient testing, eosin-5-maleimide binding, hemoglobin analysis, genetic testing, and bone marrow examination should be selected according to the clinical context.

Treatment & Management

Management begins with stabilization and removal of the precipitating factor. Severe symptomatic anemia, hemodynamic compromise, myocardial ischemia, or rapidly progressive hemolysis may require red cell transfusion, although compatibility testing can be complex in autoimmune disease. Transfusion decisions should be individualized and should not be withheld solely because serologic compatibility is difficult when the patient is clinically unstable. Folic acid supplementation is often appropriate in sustained hemolysis because erythropoiesis increases folate utilization.

Warm autoimmune hemolytic anemia is generally treated initially with corticosteroids, followed by rituximab or other steroid-sparing therapy when response is inadequate, relapse occurs, or prolonged steroid exposure is unsafe. Cold antibody-mediated disease requires thermal protection, treatment of an underlying clonal or infectious disorder, and, when indicated, complement-directed or B-cell-directed therapy. PNH is treated with complement inhibition in patients with clinically significant hemolysis, transfusion need, symptoms, thrombosis, or organ complications. Vaccination and infection prevention are critical before and during terminal complement blockade, with urgent evaluation of febrile illness.

Patients with G6PD deficiency should avoid identified oxidant drugs and chemicals and should receive prompt treatment for infection. Mechanical hemolysis requires assessment of valve function, device settings, paravalvular leakage, or structural cardiac disease. Thrombosis, acute kidney injury, electrolyte abnormalities, and gallstone complications should be managed concurrently. Corticosteroids or immunosuppressants should not be used empirically when immune hemolysis has not been established, because unnecessary treatment can cause infection, metabolic complications, and diagnostic delay.

Recent Advances / Emerging Therapies

Advances in complement biology have expanded treatment options for complement-mediated hemolysis. Long-acting C5 inhibitors, proximal complement inhibitors, and investigational factor-directed agents aim to improve control of intravascular and residual extravascular hemolysis while reducing infusion burden. Novel therapies for pyruvate kinase deficiency can improve red cell metabolism, hemoglobin concentration, and hemolytic markers in selected adults with pyruvate kinase deficiency. Improved next-generation sequencing panels are also helping identify inherited hemolytic disorders in adults previously classified as having unexplained anemia.

Digital laboratory integration and longitudinal analysis of hemolysis markers may improve detection of intermittent disease. Research is increasingly focused on precision selection of complement blockade, biomarkers that predict treatment response, safer steroid-sparing regimens for autoimmune hemolysis, and curative approaches for selected inherited disorders. These developments are promising, but long-term safety, vaccination requirements, resistance patterns, cost, and equitable access remain important considerations.

Guideline Recommendations

Guideline-consistent practice supports confirming hemolysis with multiple laboratory indicators, reviewing the smear and medication history, performing direct antiglobulin testing early, and investigating secondary causes when autoimmune hemolysis is identified. Patients with suspected thrombotic microangiopathy require urgent assessment of platelet count, renal function, coagulation studies, neurologic status, and hemolysis severity, with rapid specialist involvement when thrombotic thrombocytopenic purpura is possible. PNH testing is recommended in selected patients with unexplained intravascular hemolysis, cytopenias, aplastic anemia, or thrombosis at unusual sites.

Clinical decisions should incorporate symptoms, hemoglobin trajectory, renal and cardiac effects, transfusion requirements, thrombotic risk, comorbidities, and patient preferences rather than laboratory values alone. Specialist hematology consultation is appropriate when hemolysis is persistent, recurrent, Coombs-negative, associated with multiple cytopenias, or unexplained after initial testing. Documentation of suspected drug causes and future avoidance is essential, and all patients should receive clear instructions about symptoms requiring urgent reassessment.

Conclusion

A normal peripheral smear does not rule out hemolysis and should never outweigh a coherent biochemical and clinical pattern. The most reliable approach combines reticulocyte assessment, bilirubin, lactate dehydrogenase, haptoglobin, urinalysis, direct antiglobulin testing, expert smear review, and targeted evaluation for immune, complement-mediated, enzymatic, hereditary, infectious, and mechanical causes. Careful attention to timing, medication exposure, transfusion history, and disease-specific risk factors prevents common diagnostic errors. Early mechanism-based diagnosis improves treatment selection, limits unnecessary immunosuppression and transfusion, identifies thrombotic or renal complications, and enables timely use of targeted therapies. For clinicians, the key lesson is that unexplained hemolysis is a syndrome requiring structured investigation, even when morphology appears normal.